A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

Tolerability and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized, Placebo-Controlled Studies

(2012) Tae-Eun Kim et al.   CLINICAL THERAPEUTICS

A phase I study of DHP107, a mucoadhesive lipid form of oral paclitaxel, in patients with advanced solid tumors: Crossover comparisons with intravenous paclitaxel

(2012) Yong Sang Hong et al.   INVESTIGATIONAL NEW DRUGS

P-glycoprotein Inhibition: The Past, the Present and the Future

(2011) Richard A.J. Darby et al.   CURRENT DRUG METABOLISM

Weekly paclitaxel in the treatment of recurrent ovarian cancer

(2010) Richard D. Baird et al.   Nature Reviews Clinical Oncology

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel

(2009) Jin-Oh Kwak et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer

(2008) Joseph A. Sparano et al.   NEW ENGLAND JOURNAL OF MEDICINE